Nephros, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| NEPH | NAN.AX | AVTR | 8086.T | RMTI | NRXS | |
|---|---|---|---|---|---|---|
| Market cap | 35.33M | 882.54M | 10.60B | 236.08B | 32.45M | 86.15M |
| P/E (TTM) | 21.7 | 49.2 | 31.3 | 18.9 | — | — |
| Forward P/E | 15.5 | 56.7 | 17.6 | 13.7 | 115.0 | -25.4 |
| Price/book | 2.9 | 4.1 | 1.8 | 0.8 | 0.9 | 12.7 |
| Dividend yield | — | — | — | 2.28% | — | — |
| 1-year change | −43.06% | −32.09% | +34.63% | −8.96% | −22.21% | +159.06% |
| Today | +0.31% | +1.03% | +0.38% | +6.32% | −0.49% | +4.26% |
The closest companies by business and industry (Medical Instruments & Supplies). Prices may be delayed up to 20 min.
Latest news
All NEPH news ›Comparing Tandem Diabetes Care (NASDAQ:TNDM) & Nephros (NASDAQ:NEPH)
Posted by Mitch Edgeman on Oct 26th, 2026 Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) and Nephros (NASDAQ:NEPH – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two…
Rege Nephro Secures approximately US$10.6 Million to Advance RN-014 Toward Commercialization
The company's lead program, RN-014, recently reached LPLV (Last Patient Last Visit) in its Phase 2a clinical trial, marking an important milestone. RN-014 is a small-molecule therapeutic candidate identified through screening using an iPS…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- manilatimes.net1
- themarketsdaily.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.